Esperion Therapeutics (ESPR) Competitors $0.98 -0.02 (-1.54%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$1.03 +0.04 (+4.57%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. REPL, AVBP, CRON, XERS, DNTH, ZYBT, ANAB, KALV, ABUS, and TRVIShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Replimune Group (REPL), ArriVent BioPharma (AVBP), Cronos Group (CRON), Xeris Biopharma (XERS), Dianthus Therapeutics (DNTH), Zhengye Biotechnology (ZYBT), AnaptysBio (ANAB), KalVista Pharmaceuticals (KALV), Arbutus Biopharma (ABUS), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Replimune Group ArriVent BioPharma Cronos Group Xeris Biopharma Dianthus Therapeutics Zhengye Biotechnology AnaptysBio KalVista Pharmaceuticals Arbutus Biopharma Trevi Therapeutics Replimune Group (NASDAQ:REPL) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends. Do insiders & institutionals believe in REPL or ESPR? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by company insiders. Comparatively, 1.0% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer REPL or ESPR? In the previous week, Esperion Therapeutics had 14 more articles in the media than Replimune Group. MarketBeat recorded 18 mentions for Esperion Therapeutics and 4 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.47 beat Esperion Therapeutics' score of 0.67 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, REPL or ESPR? Replimune Group has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Do analysts rate REPL or ESPR? Replimune Group currently has a consensus target price of $19.43, suggesting a potential upside of 101.54%. Esperion Therapeutics has a consensus target price of $6.42, suggesting a potential upside of 552.10%. Given Esperion Therapeutics' higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community believe in REPL or ESPR? Esperion Therapeutics received 461 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 70.23% of users gave Esperion Therapeutics an outperform vote while only 64.02% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16964.02% Underperform Votes9535.98% Esperion TherapeuticsOutperform Votes63070.23% Underperform Votes26729.77% Is REPL or ESPR more profitable? Replimune Group has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -54.84% -42.97% Esperion Therapeutics -29.37%N/A -10.77% Which has preferable earnings and valuation, REPL or ESPR? Esperion Therapeutics has higher revenue and earnings than Replimune Group. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.07-3.14Esperion Therapeutics$332.31M0.59-$209.25M-$0.25-3.94 SummaryEsperion Therapeutics beats Replimune Group on 10 of the 18 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.98M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.547.3222.5118.54Price / Sales0.59241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book-0.266.486.734.25Net Income-$209.25M$143.41M$3.22B$248.18M7 Day Performance6.96%2.58%1.38%1.03%1 Month Performance-29.21%5.00%2.79%2.70%1 Year Performance-52.23%-3.72%15.41%4.05% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics3.4442 of 5 stars$0.98-1.5%$6.42+552.1%-51.8%$194.98M$332.31M-1.54200Upcoming EarningsAnalyst RevisionNews CoverageREPLReplimune Group4.089 of 5 stars$9.28+2.5%$19.43+109.4%+48.8%$714.39MN/A-3.02210Positive NewsAVBPArriVent BioPharma1.0364 of 5 stars$20.92+0.5%$39.00+86.4%+26.3%$711.62MN/A-8.1440Short Interest ↑News CoverageCRONCronos Group1.5306 of 5 stars$1.84+1.9%$3.50+90.7%-31.0%$707.22M$117.62M-14.12450Upcoming EarningsXERSXeris Biopharma3.5751 of 5 stars$4.42+2.4%$6.10+38.2%+156.0%$690.44M$203.07M-9.81290Upcoming EarningsPositive NewsHigh Trading VolumeDNTHDianthus Therapeutics1.7326 of 5 stars$21.36-1.4%$54.33+154.3%-3.7%$686.31M$6.24M-8.5580Upcoming EarningsNews CoveragePositive NewsZYBTZhengye BiotechnologyN/A$14.15+35.5%N/AN/A$667.40M$189.75M0.00278ANABAnaptysBio2.5138 of 5 stars$21.33+3.0%$33.63+57.6%-16.6%$654.13M$91.28M-3.51100Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsKALVKalVista Pharmaceuticals3.9024 of 5 stars$13.01+0.1%$24.83+91.0%+11.7%$646.56MN/A-3.57100Positive NewsABUSArbutus Biopharma2.0074 of 5 stars$3.34+1.5%$5.50+64.7%+34.2%$639.54M$6.17M-7.7790Positive NewsTRVITrevi Therapeutics3.5994 of 5 stars$6.59+1.9%$17.56+166.5%+141.3%$637.13MN/A-14.9820Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Replimune Group Competitors ArriVent BioPharma Competitors Cronos Group Competitors Xeris Biopharma Competitors Dianthus Therapeutics Competitors Zhengye Biotechnology Competitors AnaptysBio Competitors KalVista Pharmaceuticals Competitors Arbutus Biopharma Competitors Trevi Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESPR Stock Free ESPR Stock Alerts